Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3881MR)

This product GTTS-WQ3881MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3881MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2236MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA aVWF81
GTTS-WQ5035MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ289MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ13814MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-10987
GTTS-WQ1020MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ8482MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HTI-1088
GTTS-WQ1195MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ1085MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-838
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW